Is technology replacing the human element in hospitals and clinics, or enhancing it? In this AAMI Research Review, a pair of newly published studies exemplify how accounting for the humans that use a technology can enhance its effectiveness… and vice versa.
The growing availability of 5G networks is speeding the adoption of IoMT and allowing for new innovations, including drone delivery of medical supplies to rural areas, better surgical collaboration and 3D holograms for diagnoses and surgical planning.
The two new members bring more than 40 years of leadership and IT experience to the HUMA.AI advisory boards, following a recent round of funding and the introduction of new post-market surveillance technologies.
Next-generation, predictive analytic patient monitoring lowers healthcare costs, improves clinical outcomes and enhances the patient experience in hospital-at-home, post-acute care and chronic care management.
The committee will be discussing skin lesion analyzer technology and its application in detecting skin cancers in various patient care settings as well as the potential reclassification of approved computer-aided melanoma detection class III devices.
John Mastrototaro, Ph.D., biomedical engineer and CEO of Movano discusses strategies to improve data accuracy, the convergence of consumer wearables and medical remote monitoring devices and what healthcare providers are seeking in remote data delivery.
Randomized clinical trials are the gold standard for conducting clinical research. They are, however, fraught with issues and come with burdens to the patient, site and sponsor. Decentralized trials (DCTs) allow for a novel, agile and more cost-effective approach to an industry standard and traditional methodology. Here’s how to determine if a full or hybrid DCT is a good option for your clinical trial.
Numerous studies have explored the challenge of helping patients adhere to their medication regimens. One promising solution is “smart” medication blister packs with embedded sensors that enable caregivers to remotely monitor if—and when—doses are removed. But they can only be used if they are cyber-hardened against today’s dangerous and ever-evolving cybersecurity risks.
The COVID-19 pandemic exposed the necessity of virtual care and revealed its possibility as a more efficient means of administering treatment in an overwhelmed and understaffed infrastructure. Its fast-paced adoption highlighted the need for global standards and third-party certifications.
Old justifications or business reasons for security gaps are obsolesced. We need robust medical device cybersecurity, but we need it in a manner that is workable by both MDMs and HDOs.
